Lupin rises on getting EIR from USFDA for Chhatrapati Sambhajinagar facility

13 Nov 2025 Evaluate

Lupin is currently trading at Rs. 2055.60, up by 19.75 points or 0.97% from its previous closing of Rs. 2035.85 on the BSE.

The scrip opened at Rs. 2055.80 and has touched a high and low of Rs. 2055.80 and Rs. 2033.15 respectively. So far 12534 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1774.00 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 2057.45 and Rs. 1960.85 respectively. The current market cap of the company is Rs. 93647.67 crore.

The promoters holding in the company stood at 46.90%, while Institutions and Non-Institutions held 47.06% and 6.06% respectively.

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Chhatrapati Sambhajinagar (Aurangabad) facility, following a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2102.50 10.55 (0.50%)
05-Dec-2025 15:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1806.00
Dr. Reddys Lab 1276.05
Cipla 1521.20
Zydus Lifesciences 931.85
Lupin 2102.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×